Nordic Pharma’s Post

Not long to go until #ESMO24! Really excited to be attending along with our talented team of Inizio experts. We will be at booth 431e, ready to answer all your oncology questions. In the meantime, check out our new blog, where Heidi Bell, Group Growth Director, Inizio Evoke Europe, discusses The invisible epidemic of bias in oncology. #ESMO24 #Oncology #ReimagineHealth #OncologyTreatments

With #ASCO24 kicking off today, the Lifescience Dynamics team has touched down in Chicago. Take a look at 5 key data releases that we are looking forward to seeing this American Society of Clinical Oncology (ASCO). Our team will be onsite and discussing the latest insights from the data coming out of this year’s conference and the broader impact that it will have on the pharma industry. Get in touch with Natasha Malik, Peter Kelly, PhD and Matt Stebbings if you would like to learn more.  #ASCO24 #Oncology #LifescienceDynamics

With #ESMO24 kicking off today, the Lifescience Dynamics team has touched down in Barcelona. Take a look at 5 key data releases that we are looking forward to seeing this European Society for Medical Oncology (ESMO).   Our team will be onsite and discussing the latest insights from the data coming out of this year’s conference and the broader impact that it will have on the pharma industry.   Get in touch with Rafaat Rahmani and Natasha Malik if you would like to learn more.   #ESMO24 #Oncology #LifescienceDynamics

As ESMO Congress 2024 is approaching, attention is given to the fascinating programme. This year we are going to see lots of new data, phase I data in Presidential Symposium and many analyses from previously presented trials. That is great that nowadays, when precision oncology is developing quickly, so many talks at the Congress will cover the promising new drugs. Here is the selection of most awaited results in #PrecisionOncology from #ESMO24.

🔬 It's today! Come and meet us at the CRCL symposium in Lyon! Our representatives, Marjorie Lacourrege and Romain Teinturier, will be on hand to present two scientific posters that will mark a turning point in preclinical models and immunotherapy research. 1️⃣ Humanized Avian Xenograft Models IMMUNO-AVI-PDX™ and IMMUNO-AVI-cellDX™: These unique models accelerate the evaluation of immunotherapy and immune cell therapies with improved predictive accuracy. A real asset for preclinical research. 2️⃣ Innovative Preclinical Models: Synergizing AVI-PDX and Patient-Derived Organoid Technologies: An innovative approach combining AVI-PDX models and patient-derived organoid technologies to accelerate precision medicine in oncology and immuno-oncology. This research represents a major breakthrough for the personalization of oncology treatments, providing a better understanding of tumor responses and optimizing therapies. 📅 Come and discuss it with our experts ! #CRCL2025 #Oncology #ImmunoOncology #Immunotherapie #PrecisionMedicine #ERBC #R&D

Excited by the potential of cell-free DNA-seq for oncology research, but frustrated by library preparation systems that require time-consuming protocol optimization? Try ThruPLEX kits: - Simple, streamlined workflow - Wide range of sample inputs - Single-tube protocol - High-complexity libraries ThruPLEX kits outperform competitor kits for DNA-seq of cell-free DNA. View the data: https://ow.ly/wr6o50Uoy3f #NGS #DNA-seq #oncology

Find out what new data from the #ASCO24 congress is likely to impact the field of lower GI oncology With experts Jenny Seligmann and Dominik Modest Watch this space for a summary of the highlights during the congress #MedEd

📢 A new EOSC4Cancer deliverable is now available! EOSC4Cancer’s Deliverable 3.1 focuses on the enhancement of interoperability between clinical trial databases and Clinical Decision Support Systems (CDSS) for oncology. The document’s principal authors are Macha Nikolski of Centre national de la recherche scientifique and David Tamborero of the Karolinska Institutet working within Work Package 3. Check out the full deliverable: https://emp.onl/cO4So #cancerdata #fairdata #eosc

What does the future hold for oncology innovation? How can we connect ground-breaking clinical advancements to drive meaningful change? If you missed it, the #AxiomThinkTank and Akash Tewari from Jefferies Financial Group held a virtual townhall-style webinar, “Oncology: 2024 in Review and a Look Ahead to 2025.” Together, we reflected on 2024’s key milestones and uncovered high-potential opportunities for 2025 that could redefine the future of oncology. Watch the full-session below: https://lnkd.in/e44jwdJJ  #Oncology #BiotechInnovation #BiotechVC #Jefferies

Did you know that Australia plays a pivotal role in accelerating clinical trials? Strategically scheduled one week before ASCO, we invite you to a live webinar conducted by our thought leaders, Jeffrey Keefer and Bryce Davies Delve into the specific hurdles faced by sponsors in clinical development and learn how Australia effectively addresses these challenges, accelerating trial timelines. Don't miss this chance to explore a compelling case study highlighting Australia's pivotal role. Register now to secure your spot! https://bit.ly/3UZIA9C #DrugDevelopment #Oncology #Webinar